Announcement Summary

Entity name

NOXOPHARM LIMITED

Announcement Type

New announcement

Date of this announcement

Friday November 20, 2026

The +securities to be quoted are:

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
NOX	ORDINARY FULLY PAID	1,240,351	20/11/2026

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

NOXOPHARM LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ABN

Registration number

50608966123

1.3 ASX issuer code

NOX

1.4 The announcement is

New announcement

1.5 Date of this announcement

20/11/2026

Part 2 - Type of Issue

2.1 The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

Previous Appendix 3B details:

Announcement Date and Time	Announcement Title	Selected Appendix 3B to submit quotation request
19-Nov-2026 14:45	New - Proposed issue of securities - NOX	A placement or other type of issue

2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?
No

Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B

Placement Details

ASX +security code and description

NOX : ORDINARY FULLY PAID

Issue date

20/11/2026

Distribution Schedule

Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.

Number of +securities held	Number of holders	Total percentage of +securities held For example, to enter a value of 50% please input as 50.00
1 - 1,000		%
1,001 - 5,000		%
5,001 - 10,000		%
10,001 - 100,000		%
100,001 and over		%

Issue details

Number of +securities to be quoted

1,240,351

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Shares issued in lieu of Directors' Fees as approved by shareholders at the Annual General Meeting held on 17 November 2026.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.090700

Any other information the entity wishes to provide about the +securities to be quoted

At the 2026 Noxopharm AGM, an issue of shares was approved for Non-Executive Directors in lieu of fees accrued up to 30 June 2026. The issue price was based on the 10-trading day volume weighted average price of shares traded on the ASX up to and including 30 June 2026.

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
NOX : ORDINARY FULLY PAID	335,331,853

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
NOXAI : OPTION EXPIRING 10-SEP-2027 EX $0.1488	1,290,000
NOXAH : CONVERTIBLE NOTES	3,850,000